Trial · NCT00231842
Adjuvant Radiation Therapy With Ifosfamide in Patients With Mixed Mesodermal Tumors of the Uterus
NCT00231842, Phase 2, Completed, Montefiore Medical Center; results first posted 2019-01-23
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Adjuvant Radiation Therapy With Ifosfamide in Patients With Mixed Mesodermal Tumors of the Uterus. Trials, record NCT00231842. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00231842
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Adjuvant Radiation Therapy With Ifosfamide in Patients With Mixed Mesodermal Tumors of the Uterus
- NCT number
- NCT00231842
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 30 participants, actual
- Lead sponsor
- Montefiore Medical Center
- Conditions
- Uterine Cancer
- Interventions
- Ifosfamide, Radiation Therapy, Cisplatin
- First posted
- 2005-10-04
- Last updated
- 2019-01-23
- Results first posted
- 2019-01-23
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cycles With Hematologic Toxicities | 2 years | Out of 162 planned cycles, a total of 138 cycles (85%) were administered. Number of cycles during which participants with grades 3 and 4 experienced hematologic toxicities are reported. Most of the toxicities were self-limiting. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Cycles With Hematologic Toxicities | 2 years | Cycles | NUMBER |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Cycles With Hematologic Toxicities | Grade 3 Toxicity | Neutropenia | 11 | Cycles | |
| Cycles With Hematologic Toxicities | Grade 4 Toxicity | Neutropenia | 14 | Cycles | |
| Cycles With Hematologic Toxicities | Grade 3 Toxicity | Anemia | 6 | Cycles | |
| Cycles With Hematologic Toxicities | Grade 4 Toxicity | Anemia | 0 | Cycles | |
| Cycles With Hematologic Toxicities | Grade 3 Toxicity | Thrombocytopenia | 6 | Cycles | |
| Cycles With Hematologic Toxicities | Grade 4 Toxicity | Thrombocytopenia | 2 | Cycles |
Source ClinicalTrials.gov
Participant flow7
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Chemotherapy and Radiation Therapy | 30 | |
| Overall Study | Initiated Therapy | Chemotherapy and Radiation Therapy | 27 | |
| Overall Study | Completed First 3 Cycles | Chemotherapy and Radiation Therapy | 27 | |
| Overall Study | Completed Prescribed RT | Chemotherapy and Radiation Therapy | 27 | |
| Overall Study | Completed Full Prescribed Therapy | Chemotherapy and Radiation Therapy | 19 | |
| Overall Study | COMPLETED | Chemotherapy and Radiation Therapy | 19 | |
| Overall Study | NOT COMPLETED | Chemotherapy and Radiation Therapy | 11 |
Source ClinicalTrials.gov
Adverse events1
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Neutropenia | Blood and lymphatic system disorders | Chemotherapy and Radiation Therapy | 13 | 27 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Chemotherapy and Radiation Therapy | 0 | 27 |
| Total, other adverse events | Chemotherapy and Radiation Therapy | 0 | 27 |
| Total, serious adverse events | Chemotherapy and Radiation Therapy | 13 | 27 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 22055846 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00231842
GET https://conductscience.org/api/trials/v1/NCT00231842/registered